(205 days)
Not Found
Not Found
No
The summary describes a standard in vitro diagnostic immunoassay for measuring SHBG levels. There is no mention of AI, ML, image processing, or any other technology typically associated with AI/ML in medical devices.
No
The text describes the device as an in vitro diagnostic immunoassay used to quantify a substance in bodily fluids to aid in the diagnosis of a disorder, not to treat it.
Yes
Explanation: The "Intended Use / Indications for Use" section explicitly states "The ADVIA Centaur® SHBG assay is an in vitro diagnostic immunoassay..." and "The ADVIA Centaur SHBG assay is intended for use as an aid in the diagnosis of androgen disorders."
No
The device is an in vitro diagnostic immunoassay, which involves chemical reagents and laboratory equipment (the ADVIA Centaur systems), not solely software.
Yes, based on the provided text, this device is an IVD (In Vitro Diagnostic).
The "Intended Use / Indications for Use" section explicitly states:
- "The ADVIA Centaur® SHBG assay is an in vitro diagnostic immunoassay..."
- "The ADVIA Centaur SHBG Calibrators are for in vitro diagnostic use..."
- "The ADVIA Centaur SHBG Master Curve Material are for in vitro diagnostic use..."
These statements clearly indicate that the device and its associated components are intended for use in diagnostic procedures performed outside of the living body, which is the definition of an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
The ADVIA Centaur® SHBG assay is an in vitro diagnostic immunoassay for the quantitative determination of sex hormone-binding globulin (SHBG) in human serum and plasma using the ADVIA Centaur systems.
The ADVIA Centaur SHBG assay is intended for use as an aid in the diagnosis of androgen disorders.
The ADVIA Centaur SHBG Calibrators are for in vitro diagnostic use in calibrating the ADVIA Centaur sex hormone-binding globulin (SHBG) assays.
The ADVIA Centaur SHBG Master Curve Material are for in vitro diagnostic use in the verification of calibration and reportable range in the ADVIA Centaur sex hormonebinding globulin (SHBG) assay.
Product codes
CDZ, JIT, JJX
Device Description
Not Found
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Not Found
Key Metrics
Not Found
Predicate Device(s)
Not Found
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.1680 Testosterone test system.
(a)
Identification. A testosterone test system is a device intended to measure testosterone (a male sex hormone) in serum, plasma, and urine. Measurement of testosterone are used in the diagnosis and treatment of disorders involving the male sex hormones (androgens), including primary and secondary hypogonadism, delayed or precocious puberty, impotence in males and, in females hirsutism (excessive hair) and virilization (masculinization) due to tumors, polycystic ovaries, and adrenogenital syndromes.(b)
Classification. Class I.
0
Image /page/0/Picture/0 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized symbol that resembles three abstract human figures or waves.
Food and Drug Administration 10903 New Hampshire Avenue Document Mail Center - WO66-0609 Silver Spring, MD 20993-0002
Siemens Healthcare Diagnostics c/o Ms. Clare Santulli Sr. Regulatory Specialist 511 Benedict Avenue Tarrytown, NY 10591-5097
JAN 1 4 2010
Re: K091867
Trade name: ADVIA Centaur SHBG Ready Pack Regulation Number: 21 CFR 862.1680 Regulation Name: Testosterone test system Regulatory Class: Class I (reserved) Product Code: CDZ, JIT, JJX Dated: December 30, 2009 Received: December 31, 2009
Dear Ms. Santulli:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial eguivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR-Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820).
1
Page 2
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or ( 301 ) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Courtney C. Harper, Ph.D. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
...
2
Indication for Use
510(k) Number (if known): K091867
ADVIA Centaur® SHBG Assay Device Name(s): ADVIA Centaur® SHBG Calibrators ADVIA CENTAUR® SHBG Master Curve Material
Indication For Use: '
The ADVIA Centaur® SHBG assay is an in vitro diagnostic immunoassay for the quantitative determination of sex hormone-binding globulin (SHBG) in human serum and plasma using the ADVIA Centaur systems.
The ADVIA Centaur SHBG assay is intended for use as an aid in the diagnosis of androgen disorders.
The ADVIA Centaur SHBG Calibrators are for in vitro diagnostic use in calibrating the ADVIA Centaur sex hormone-binding globulin (SHBG) assays.
The ADVIA Centaur SHBG Master Curve Material are for in vitro diagnostic use in the verification of calibration and reportable range in the ADVIA Centaur sex hormonebinding globulin (SHBG) assay.
Prescription Use --------イ (21 CFR Part 801 Subpart D)
And/Or
Over the Counter Use (21 CFR Part 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)
Carol C. Benson
Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety
510(k) K091867